RE:Shelf Prospectusfredgoodwinson wrote: Can`t see why they pulled the Shelf Prospectus as its`existence didn`t stop them taking other routes but maybe it was a Statement of Intent - the intent being to fund the imperative element of Phase II without recourse to further dilution beyond existing Warrants.
There is a maximum number of 125 Patients in the Trial.
The feedback from the enhanced 3200 appears to give them both the ability to prognose a Complete Response and to sustain a treatment until they have achieved one. They will not be waiting anxiously (as we may be!) for outcomes.They will have seen them in real time with their own two eyes.
Seems to have been strongly implied at the MSAB meeting that the Trial might be paused to request the FDA`s consent to commercialise after obtaining a 30% CR - with a further implication that such a request might by sympathetically received.If so they would need to treat a maximum of 45 patients (including a few to allow for those who don`t complete the Trial for other reasons) and probably less.
This is the goal that the Company may have set itself - to fund this element of the Trial entirely from existing Warrants. Now that the Trial is ’live’ they will have a much greater arsenal of NRs to counterbalance the selling. It can`t make sense to issue new stock now when they will know very very soon if they are achieving objectives which will in turn allow them to get a much better price in future issues.
It has been RW`s strategy over the years to minimise the number of shares on issue and thereby maximise shareholder value. Don`t see this changing now.
In the last ann Dr.Shirazi stated that "Theralase stakeholders should be excited about the ability of the Company to execute on its strategic objectives…”
If that excitement stems from the possibility of achieving commercialisation with less than 200m shares on issue then they certainly should.
Fredgoodwinson, you can be forgiven for always conjuring up the bright side and ignoring the facts since after all you are one of the lead pumpers of this stock but I think it would be a stretch of the imagination to propose that the FDA would give commercial approval for a new and I might add, an unorthodox medical treatment whose science has very little history for the FDA to draw upon based on only 30 or 40 patients. That would fly in the face of how the FDA operates where big pharma expects to pay hundreds of millions to get a drug approved and TLT can get away with just a few millions from warrant money. I'm having difficulty wrapping my head around that one. I guess you are suggesting we have a slam dunk in the making and the phase 2 testing is nothing more than an annoyance keeping you from the big pay day.
I also take issue with your portrayal of RW minimizing the number of shares as a strategy. Was it intentional or was he unable to find the willingness to invest when petitioniing the capital markets? If you recall not too long ago they tried for a $10M PP via the Stockhouse Deal Room only to close it after bringing in 1/10th of what they requested. Where was your strategy there?
IMO, there is too much needless confusion surrounding this stock. Investors are confused when the actual treating of patients will start, if the FDA will participate and when and the elephant in the room, how this company will pay for a an expected 3 year trial? Maybe it's just my impression but to me it seems the new CEO is just as not forthcoming as the old regime. Has anybody seen him give an interview anywhere?